UPClytics
EnglishDeutsch
Sign inSign up
View all cases

UPC CFI 496/2024

Sep 2, 2024·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Parent infringement case:UPC CFI 146/2024

Case details
Status
Case Closed
Action
Counterclaim for revocation
Category
Counter Claim for Revocation
Parties
Claimants
Reps: Konstantin Schallmoser
Division
Munich LD
Judges
Technology
Pharmaceuticals · Small Molecule · Pharmaceutical & Medical
Language
English
First decided
Dec 12, 2025
Documents
Document titleDatePublic
Receipt2026-03-31Not public
Cover sheet2026-03-31Not public
Exhibit Defendant2026-03-31Not public
Application document Defendant2026-03-31Not public
Note2026-03-11Not public
Note2026-02-06Not public
Receipt2026-02-04Not public
Cover sheet2026-02-04Not public
Application document Claimant2026-02-04Not public
Receipt2026-01-12Not public
Cover sheet2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Application document Applicant2026-01-12Not public
action.phaseChange.caseClose2025-12-16Not public
Decision2025-12-16Public
action.issueDecision.decision2025-12-12Not public
Decision2025-12-12Not public
Other Documents2025-11-25Not public
Cover sheet2025-10-08Not public
Exhibit2025-10-08Not public
Further pleadings2025-10-08Not public
Receipt2025-10-08Not public
Cover sheet2025-10-08Not public
Further pleadings2025-10-08Not public
Exhibit2025-10-08Not public
Receipt2025-10-08Not public
oral hearing reference - IC2025-09-15Not public
oral hearing reference - IC2025-09-15Not public
Fix-Interim-Conference-Date2025-09-10Not public
Interim-Conference-Decision2025-09-10Not public
Written-Procedure-Closure2025-09-10Not public
Acknowledgement-of-lodging2025-08-09Not public
Rejoinder2025-08-09Not public
Acknowledgement-of-lodging2025-08-09Not public
Rejoinder2025-08-09Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Exhibit No. B.392025-08-08Not public
Exhibit No. B.402025-08-08Not public
Exhibit No. B.2.2.22025-08-08Not public
Exhibit No. 0.52025-08-08Not public
Exhibit No. B.302025-08-08Not public
Exhibit No. B.22.1bis2025-08-08Not public
Exhibit No. B.412025-08-08Not public
Exhibit No. B.372025-08-08Not public
Exhibit No. B.432025-08-08Not public
Exhibit No. B.362025-08-08Not public
Rejoinder2025-08-08Not public
Exhibit No. B.352025-08-08Not public
Exhibit No. B.2.2.12025-08-08Not public
Exhibit No. B.342025-08-08Not public
Exhibit No. B.382025-08-08Not public
Exhibit No. B.312025-08-08Not public
Exhibit No. B.322025-08-08Not public
Exhibit No. B.422025-08-08Not public
Exhibit No. B.332025-08-08Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Application-RoP2932025-06-27Not public
Application2025-06-27Not public
Hearing-Dates2025-01-24Not public
scheduling IC and OH for CC2025-01-24Public
Hearing-Dates2025-01-24Not public
Outcome of the Order2025-01-17Not public
R 305 second - final2025-01-17Public
Hearing Reference2025-01-16Not public
Hearing Reference2025-01-16Not public
Hearing-Dates2025-01-13Not public
R 305 second- oral comments2025-01-13Not public
Receipt2025-01-09Not public
Application2025-01-09Not public
Exhibit No. A.02.22025-01-09Not public
Outcome of the Order2024-12-19Not public
extension request2024-12-19Public
Receipt2024-12-13Not public
Extension request2024-12-12Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
epoUploadDocumentsWorkflow2024-09-17Not public
Document from EPO2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Letter for Service2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Panel-Appointment2024-09-11Not public
EPO-Request-for-case-pending2024-09-11Not public
Acknowledgement-of-lodging2024-09-11Not public
Formal-checks_Notification-of-positive-outcome2024-09-11Not public
Decision T 0096/20 of the EPO Boards of Appeal dated 22 April 20212024-09-02Not public
Tannock, et al., J. Clin. Oncol. 1996, 14(6), 1756-64.2024-09-02Not public
de Bono et al. article (cf. D15) as published on October 2, 20102024-09-02Not public
Winquist et al., The Canadian Journal of Urology, 15(1), February 20082024-09-02Not public
Decision T 0239/16, dated 13 September 20072024-09-02Not public
WO 96/30355 A1 published 3 October 19962024-09-02Not public
“Un projet de medicament stoppé in extremis”, Les Echos, 22 Dec 20092024-09-02Not public
Attard et al, Pathologie Biologie 54 (2006) 72-842024-09-02Not public
Fossà, et al., J. Clin. Oncol. 2001, 19(1), 62-71.2024-09-02Not public
ICH Harmonised Tripartite Guideline “General Considerations for Clinical Trials E8” dated 17 July 19972024-09-02Not public
US 61/256160, first priority document2024-09-02Not public
Declaration by Prof. Dr Kurt Miller dated 12 May 20212024-09-02Not public
Blog post by Dr Barry Mirtsching on “the Prostate Cancer blog”, dated 12 October 20072024-09-02Not public
Expert Opinion Dr. Kai Gevers dated 26 March 20212024-09-02Not public
FDA prescribing information of JEVTANA (cabazitaxel); revised in June 20102024-09-02Not public
FDA label for Taxotere (2007)2024-09-02Not public
EMA “ICH Topic E 8 General Considerations for Clinical Trials”, published March 1998.2024-09-02Not public
Extract relating to trial no. NCT00417079 dated 11 September 20092024-09-02Not public
Tribunal Judiciaire de Paris, Ordonnance de référé, 17 June 2021, N° RG 21/53849 – N° Portalis 352J-W-B7F-CUJG22024-09-02Not public
WO 2011/051894, original application2024-09-02Not public
Sartor et al., Urology 52 (2), 1998, 252-2562024-09-02Not public
Goetz et al., Clinical Pharmacology, Proceedings of ASCO Volume 20 20012024-09-02Not public
Document “Information for the patient concerning the clinical study 42446 02041”, cited as “document 55” in EPO Boards o2024-09-02Not public
“Un projet de medicament stoppé in extremis”, Les Echos, 22 Dec 20092024-09-02Not public
Reuters newsclip confirming the date of D23 (AE14)2024-09-02Not public
Shigeta et al., Correspondence, The Lancet, 377, 2011, 121-1222024-09-02Not public
Expert Opinion Dr. Kai Gevers dated 26 March 20212024-09-02Not public
Document “Zeltia Junta General de Accionistas 2003”, cited as “document D2”in EPO Boards of Appeal decision T 2506/122024-09-02Not public
Sternberg et al. Oncology 2013;85: 208-2152024-09-02Not public
Summary of product characteristics of Taxotere; revision of November 20082024-09-02Not public
October 2008 version of the Helsinki Declaration2024-09-02Not public
Mita et al., Clin Cancer Res 2009; 15(2) published 15 January 20092024-09-02Not public
Declaration by Dr Oliver Sartor dated 23 June 2016 filed in Case IPR2016-00712, Patent US 8,927,5922024-09-02Not public
Albarqouni, “Tutorial about Hazard Ratios – Students 4 Best Evidence”, https://s4be.cochrane.org/blog/2016/04/05/tutoria2024-09-02Not public
Galletti et al., ChemMedChem 2007, 2, 920-9422024-09-02Not public
Jaehde, Lehrbuch der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-2024-09-02Not public
Curriculum Vitae of Prof. Dr. Kurt Miller2024-09-02Not public
Decision of the EPO Boards of Appeal T1806/18 dated 21 October 20212024-09-02Not public
Pivot et al., Annals of Oncology, 19, 2008, 1547-15522024-09-02Not public
Guidance document entitled “Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer – second line afte2024-09-02Not public
Declaration by Dr. Alton Oliver Sartor, M.D., December 23, 20202024-09-02Not public
Sanofi-aventis Press Release, 21 December 20092024-09-02Not public
Rosenberg et al., Cancer 2007, 110(3), 556-5632024-09-02Not public
Summary of product characteristics of Jevtana®, Sanofi Genzyme, April 20172024-09-02Not public
Bissery et al., Pharmacology and experimental therapeutics, Proceedings of the American Association for Cancer Research,2024-09-02Not public
Blog posts by Dr Barry Mirtsching on the “Center for Oncology Research & Treatment-Dallas, TX Innovative Cancer Treatmen2024-09-02Not public
Aller et al. Proceedings of the American Association for Cancer Research 2000, 41: 302, Abstract #19232024-09-02Not public
Summary of product characteristics of Jevtana®, Sanofi Genzyme, April 20172024-09-02Not public
Beardsley et al., Curr. Op. Support. Palliat. Care 2008, 2(3), 161-1662024-09-02Not public
Gaisky et al., Nature Reviews, Drug Discovery, 9, 2010, 6772024-09-02Not public
Sanchez et al. Prostate 2009 (15 September) 69: 1448- 14592024-09-02Not public
EMA Guideline on the Evaluation of Anticancer Medicinal products in Man, 20062024-09-02Not public
Sanofi-Aventis Annual Review, 17 April 20092024-09-02Not public
Sartor, Endpoints in prostate cancer clinical trials. Urology 2002, 60, 101-1082024-09-02Not public
T 3165/19 of the EPO Boards of Appeal dated 9 January 20232024-09-02Not public
WO 2005/028462, published 31 March 20052024-09-02Not public
Counterclaim for revocation2024-09-02Not public
Figg et al., Cancer Biology & Therapy, 10, 2010, 1233-12342024-09-02Not public
Declaration by Dr Samuel Denmeade dated 30 April 20212024-09-02Not public
Pal et al., Clinical Interventions in Aging, 5, 2010, 395-4022024-09-02Not public
Sanofi Press Release, “A promising R&D portfolio, well positioned to deliver future growth”, September 17, 2007.2024-09-02Not public
Protocol of clinical trial NCT00417079 (“XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Ref2024-09-02Not public
USPTO Decision dated 21 September 2017, Case IPR2016-00712, Patent US 8,927,5922024-09-02Not public
Berthold et al., Ann. Oncol., 19, 2008, 1749-17532024-09-02Not public
Patentee’s response dated 4 January 2021 to the Summons to oral proceedings in examination proc.2024-09-02Not public
Sava, et al., Expert Rev. Anticancer Ther. 2005, 5(1), 53-62.2024-09-02Not public
Leaflet “XRP6258 and XRP9881 Novel Taxoids” by Aventis Pharmaceuticals Inc., 20032024-09-02Not public
Blog posts by Dr Barry Mirtsching on the “Center for Oncology Research & Treatment-Dallas, TX Innovative Cancer Treatmen2024-09-02Not public
Fundamental statistics – Educational slide module, date of preparation: February 2023, Across T2D – Academy for cardiova2024-09-02Not public
US 2005/0065138 A1, published 24 March 20052024-09-02Not public
Tannock et al., J. Clin. Oncol. 1989, 7(5), 590-7.2024-09-02Not public
de Bono et al., Lancet, 376, 2010, 1147-11542024-09-02Not public
Decision T 2506/12 of the EPO Boards of Appeal dated 4 October 20162024-09-02Not public
Jaehde, Lehrbuch der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-2024-09-02Not public
Tribunal Judiciaire de Paris, Ordonnance de référé, 17 June 2021, N° RG 21/53849 – N° Portalis 352J-W-B7F-CUJG22024-09-02Not public
MPEP Section 6012024-09-02Not public
Assignment before the USPTO2024-09-02Not public
Tannock et al., N Engl J Med 2004, 351(15), 1502-15122024-09-02Not public
EMA Assessment Report for Jevtana (cabazitaxel), 20 January 20112024-09-02Not public
List of documents from the EPO opposition proceedings (includes further documents on which this statement of defence and2024-09-02Not public
T 2963/19 of the EPO Boards of Appeal dated 18 March 20222024-09-02Not public
Oh et al., Urology, 2006, 67:1235-1240.2024-09-02Not public
Expert declaration by Prof. Muller including Annexes 1 to 5 cited therein2024-09-02Not public